The Comparison of serotype-specific IgG and OPK activity between PCV7 and PPV23 among elderly patients

The Comparison of serotype-specific IgG and OPK activity between PCV7 and PPV23 among elderly patients - The Comparison of immunogenecity between PCV7 and PPV23 among elderly patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006132

Enrollment

100

Registered

2011-08-12

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non

Interventions

PCV7(Prevenar&amp

reg

) PPV23(Pneumovax&amp

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)written informed consent obtained from the subject. 2)healthy adults aged 65 years or older at time of the first vaccination.

Exclusion criteria

Exclusion criteria: 1)history of previous administration of PCV7 or PPV23. 2)history of anaphlractic reaction to diphtheria toxin. 3)dementia patinets. 4)patients who we are not able to follow up more than 1 month. 5)patients with fever or flu-like syndrome. 6)patients who we consider inappropriate.

Design outcomes

Primary

Measure	Time frame
serotype-specific IgG and OPK activity after 1 month	—

Secondary

Measure	Time frame
serotype-specific IgG and OPK activity from 1 year to 5 years incident ratio of pneumoniae, moribidity due to pneumonaie, total morbidity up to 5 years	—

Countries

Japan

Contacts

Public ContactHo Namkoong

Keio University School of Medicine Department of Medicine Division of Pulmonary Medicine

hounamugun@gmail.com03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026